Daxor Insiders Are Buying: But What Does the CEO's Past Sale Signal?

The smart money is watching the CEO's wallet. When the man at the top is buying and selling at the same time, it's a classic red flag. Michael Feldschuh, Daxor's CEO, has been a busy insider, but his pattern is a study in contradiction. In December 2025, just weeks before the company's major corporate update, he made a significant purchase. On December 9, he bought 37,500 shares at $12.50 per share, a move that looked like a bet on the company's new momentum. Yet, just months earlier, on April 4, 2025, he sold a massive block of stock. That transaction was the largest single insider sale by the CEO in the past year: 16,277 shares at $7.89 per share.

That April sale is the puzzle. He sold at a price well below the stock's current level and just months before a major corporate update. This timing is a pattern sometimes seen before a stock's price stagnation. The CEO was selling into a period of reported growth and FDA clearance, a move that looks more like a profit-taking than a vote of confidence. It suggests he had a clear exit strategy for a portion of his holdings at a time when the company was hyping its inflection point.

The bottom line is a lack of alignment. The CEO's skin in the game is mixed. He bought heavily in December, but the scale of that purchase doesn't erase the earlier, large sale. When a CEO sells a major block just before a positive corporate update, it raises a question: what did he know that the market didn't? For the unwary, this is a trap. The insider filings show a leader who is both betting on the future and cashing out from the past. In this setup, the smart money would watch the CEO's wallet more closely than his press release.

Skin in the Game: Insider Accumulation vs. Public Float

The numbers tell a clearer story than the CEO's mixed signals. While Michael Feldschuh's wallet has been busy, the broader executive team is showing a unified front. Over the past six months, all five insider trades have been purchases. That's a powerful alignment of interest among the leadership. The CFO, Robert J. Michel, has been particularly active, making multiple buys, including a major purchase of 37,500 shares at $12.50 per share on December 9, 2025. Other officers, like Chief Scientific Officer Jonathan Adam Feldschuh, have also been buying, with a direct purchase of 225,000 shares at $12.50 per share on the same day.

This concentrated buying by the inner circle suggests genuine smart money confidence. It's a bet that the company's clinical validation and growing test volume are just the start. Daxor has a solid track record, with over 75,000 tests performed and a foundation of peer-reviewed studies. That history of clinical validation is the kind of substance that attracts institutional interest. The data shows it: in the fourth quarter of 2024, several institutional investors made notable moves, including Renaissance Technologies LLC adding 13,000 shares and UBS Group AG increasing its position by over 110%.

The bottom line is a shift in the ownership narrative. The CEO's past sale may have been a profit-taking move, but the recent pattern of purchases by him and his key lieutenants signals a different bet. They are putting more skin in the game at a higher price, likely because they see the company's clinical foundation and market expansion potential as a catalyst. For the smart money, this isn't about a single CEO's contradictory moves; it's about the collective accumulation by those who know the business best.

The Whale Wallet: Capital Raise and Catalysts Ahead

The company has the fuel and the catalyst. In January 2026, Daxor raised $9 million in a capital raise, providing the cash needed to drive its commercial rollout. This is the kind of institutional support that signals confidence. Now, the market is waiting for the new BVA™ analyzer to convert that potential into revenue. The device is FDA-cleared, a critical step, but it must now prove its ability to drive growth. The stock's premium valuation hinges entirely on this next phase of execution.

The smart money is watching for two things. First, the commercial traction of the new analyzer. The company's recent financials show a 45% increase in operating division revenue for 2025, driven by diagnostic kits and military contracts. That's the foundation. The new analyzer needs to accelerate that trend. Second, look for institutional accumulation. The recent insider buying by the CEO and CFO is a strong signal, but the real test is whether major funds are following. Watch the 13F filings for evidence of broader institutional accumulation alongside the insiders. That would confirm the smart money sees a clear path from clinical validation to commercial scale.

The bottom line is a setup. Daxor has the capital and the product. The insider bets suggest they believe in the path. For the stock to justify its move, the new analyzer must start moving the needle on the top line. Until then, the whale wallet is full, but the market is waiting for the whale to start swimming.